Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1183/13993003.01579-2017 http://scihub22266oqcxt.onion/10.1183/13993003.01579-2017 29437941!ä!29437941 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+Respir+J 2018 ; 51 (2): ä Nephropedia Template TP {{tp|p=29437941|t=2018. Intravenous magnesium sulfate for acute wheezing in young children: a randomised double-blind trial |pdf=|usr=}}{{29437941}} gab.com Text Intravenous magnesium sulfate for acute wheezing in young children: a randomised double-blind trial JO: Eur Respir J http://www.kidney.de/pget.php?&tw=1&pmid=29437941 #FOAvip Magnesium sulfate has been shown to be an effective treatment in older children with asthma exacerbations, but it has not been investigated in acute severe virus-induced wheezing in young children.The study enrolled 61 children aged 6 months to 4 years. Inclusion criteria were severe wheezing, classified as a score of >/=6 points as assessed by the Respiratory Distress Assessment Instrument (RDAI) after initial treatment with salbutamol, and the symptoms of acute viral infection. The children were randomly allocated to receive either an infusion of magnesium sulfate (40 mg.kg(-1)) or 0.9% sodium chloride as a placebo infusion for 20 min. Primary outcome measure was mean change in RDAI scores from baseline to 6 h after the treatment.Change in the severity of wheezing from baseline to 6 h after the treatment, as measured by mean+/-sd RDAI scores, was 4.7+/-2.6 in the magnesium sulfate group and 4.2+/-4.2 in the placebo group (difference 0.5, 95% CI -1.3 to 2.3, p=0.594).Intravenous magnesium sulfate was ineffective in treating acute severe virus-induced wheezing in young children, in contrast to the previous efficacy demonstrated in older children. Twit Text FOAVip Intravenous magnesium sulfate for acute wheezing in young children: a randomised double-blind trial ????Eur Respir J http://www.kidney.de/pget.php?&tw=1&pmid=29437941 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29437941 #FOAvip English Wikipedia <ref>{{Cite pmid|29437941}}</ref> Intravenous magnesium sulfate for acute wheezing in young children: a randomised double-blind trial #MMPMID29437941 Pruikkonen H; Tapiainen T; Kallio M; Dunder T; Pokka T; Uhari M; Renko M Eur Respir J 2018[Feb]; 51 (2): ä PMID29437941show ga Magnesium sulfate has been shown to be an effective treatment in older children with asthma exacerbations, but it has not been investigated in acute severe virus-induced wheezing in young children.The study enrolled 61 children aged 6 months to 4 years. Inclusion criteria were severe wheezing, classified as a score of >/=6 points as assessed by the Respiratory Distress Assessment Instrument (RDAI) after initial treatment with salbutamol, and the symptoms of acute viral infection. The children were randomly allocated to receive either an infusion of magnesium sulfate (40 mg.kg(-1)) or 0.9% sodium chloride as a placebo infusion for 20 min. Primary outcome measure was mean change in RDAI scores from baseline to 6 h after the treatment.Change in the severity of wheezing from baseline to 6 h after the treatment, as measured by mean+/-sd RDAI scores, was 4.7+/-2.6 in the magnesium sulfate group and 4.2+/-4.2 in the placebo group (difference 0.5, 95% CI -1.3 to 2.3, p=0.594).Intravenous magnesium sulfate was ineffective in treating acute severe virus-induced wheezing in young children, in contrast to the previous efficacy demonstrated in older children. |Acute Disease[MESH] |Administration, Intravenous[MESH] |Albuterol/therapeutic use[MESH] |Asthma/*drug therapy[MESH] |Bronchodilator Agents/*administration & dosage[MESH] |Child, Preschool[MESH] |Double-Blind Method[MESH] |Dyspnea/etiology[MESH] |Female[MESH] |Finland[MESH] |Humans[MESH] |Infant[MESH] |Logistic Models[MESH] |Magnesium Sulfate/*administration & dosage[MESH] |Male[MESH] |Respiratory Sounds/*drug effects/etiology[MESH] |Severity of Illness Index[MESH]Intravenous magnesium sulfate for acute wheezing in young children: a (epmc).pdf DeepDyve Pubget Overpricing